Al's Comment:

 This is significanct because it is the first time a clinical trial ever reported success for Glioblastomas using targeted therapies.  This is only for patients with a rare mutation known as v600E in the BRAF gene.   The drugs  are approved for other diseases so can be used off label right now:dabrafenib and trametinib.  So check your pathology report - no matter what tumor type you have - for this mutation.

We have been using this combination for patients in our patient navigation program and have seen some good results!


Posted on: 11/25/2021

Targeted Drug Combo Shows Unprecedented Activity in Some Aggressive Brain Tumors

 


Click HERE to return to brain tumor news headlines.


Our privacy / cookie policy has changed.
Click
HERE to read it!